---
title: "NHS National Framework Agreement for the Supply of products for the management of Hereditary Angioedema"
ocid: "ocds-h6vhtk-0314ad"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-0314ad"
markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-0314ad.md"
json_url: "https://d3tenders.com/contract/ocds-h6vhtk-0314ad.json"
source: "Find A Tender Service"
current_stage: "Award"
buyer: "NHS ENGLAND"
published: "2022-07-21"
---

# NHS National Framework Agreement for the Supply of products for the management of Hereditary Angioedema

Buyer: NHS ENGLAND  
Current stage: Award  
OCID: ocds-h6vhtk-0314ad

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-0314ad)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-0314ad.json)

## Summary

The NHS England is conducting an open procurement process titled "NHS National Framework Agreement for the Supply of Products for the Management of Hereditary Angioedema." This tender falls under the pharmaceutical products category and is part of the goods procurement sector. The framework commenced on 1 July 2022 and will last for 18 months, with an option for extension up to a total of 48 months. Interested suppliers must prepare for submission before the tender period ends on 16 March 2022 and ensure they meet the needs of various NHS bodies across the UK.

This framework agreement offers significant growth opportunities for businesses, particularly those in the pharmaceutical and healthcare supply sectors. Companies that manufacture or supply medicines, especially those related to blood products and plasma extracts, would be well-positioned to respond to this tender. Additionally, smaller businesses with innovative solutions or niche products that can meet the NHS's stringent quality and supply criteria may find the tender particularly advantageous, as price is not the sole criterion for contract awards.

## Notice

National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for a list of the purchasing points.

### Lot Information

Lot 1 - C1 Esterase - Recombinant IV (acute treatment)

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

Options: Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

Lot 3 - C1 Esterase - Plasma derived IV (prophylaxis treatment)

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

Options: Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

Lot 6 - Lanadelumab

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

Options: Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

Lot 7 - Berotralstat

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

Options: Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

Lot 2 - C1 Esterase - Plasma derived IV (acute treatment)

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

Options: Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

Lot 4 - C1 Esterase - Plasma derived Subcut (prophylaxis treatment)

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

Options: Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

Lot 5 - Icatibant

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.

Options: Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months

Lot 1 - C1 Esterase - Recombinant IV (acute treatment)

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.

Additional CPV Codes:
33141520 - Plasma Extracts
33141510 - Blood Products

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months

Lot 3 - C1 Esterase - Plasma derived IV (prophylaxis treatment)

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.

Additional CPV Codes:
33141520 - Plasma Extracts
33141510 - Blood Products

Options: Option or options to extend at the Authority's discretion for a period or periods up to a a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months

Lot 6 - Lanadelumab

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.

Additional CPV Codes:
33141520 - Plasma Extracts
33141510 - Blood Products

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months

Lot 7 - Berotralstat

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.

Additional CPV Codes:
33141520 - Plasma Extracts
33141510 - Blood Products

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months

Lot 2 - C1 Esterase - Plasma derived IV (acute treatment)

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.

Additional CPV Codes:
33141520 - Plasma Extracts
33141510 - Blood Products

Options: Option or options to extend at the Authority's discretion for a period or periods up to a a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months

Lot 4 - C1 Esterase - Plasma derived Subcut (prophylaxis treatment)

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.

Additional CPV Codes:
33141520 - Plasma Extracts
33141510 - Blood Products

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months

Lot 5 - Icatibant

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.

Additional CPV Codes:
33141520 - Plasma Extracts
33141510 - Blood Products

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Find A Tender Service |
| Latest notice | https://www.find-tender.service.gov.uk/Notice/019862-2022 |
| Notice type | Tender Notice |
| Procurement type | Framework |
| Procurement category | Goods |
| Procurement method | Open |
| Procurement method details | Open procedure |
| Tender suitability | Not specified |
| Awardee scale | Large, SME |
| All stages | Tender, Award |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 21 Jul 2022 |
| Submission deadline | 16 Mar 2022 |
| Future notice date | Not specified |
| Award date | 19 Jun 2022 |
| Contract period | 30 Jun 2022 - 31 Dec 2023 |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | £198,666,666 |
| Lots value | £7 |
| Awards value | Not specified |
| Contracts value | £1 |

## Status

| Field | Value |
| --- | --- |
| Tender status | Complete |
| Lots status | Active, Cancelled |
| Awards status | Active |
| Contracts status | Active |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | NHS ENGLAND |
| Additional buyers | THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND) |
| Locality | RUNCORN |
| Post town | Warrington |
| Postcode | WA7 2ES |
| Country | England |
| ITL 1 | TLE Yorkshire and The Humber |
| ITL 2 | TLE4 West Yorkshire |
| ITL 3 | TLE42 Leeds |
| Local authority | Leeds |
| Electoral ward | Little London & Woodhouse |
| Westminster constituency | Leeds Central and Headingley |
| Delivery location | Not specified |

## Supplier

| Field | Value |
| --- | --- |
| Number of suppliers | 10 |
| Supplier names | ACCORD-UK; BIOCRYST IRELAND; CELIX PHARMA; CIPLA; CSL BEHRING; MARTINDALE PHARMA; PHARMING GROUP; PIRAMAL CRITICAL CARE; TAKEDA; WOCKHARDT |

## CPV Codes

### Divisions

- 33 - Medical equipments, pharmaceuticals and personal care products

### Codes

- 33141510 - Blood products
- 33141520 - Plasma extracts
- 33600000 - Pharmaceutical products

## Release History

- 21 Jul 2022 at 10:44 - TenderUpdate - Tender Notice - https://www.find-tender.service.gov.uk/Notice/019862-2022
- 19 Jul 2022 at 16:19 - Award - Award Notice - https://www.find-tender.service.gov.uk/Notice/019699-2022
- 8 Feb 2022 at 15:38 - Tender - Tender Notice - https://www.find-tender.service.gov.uk/Notice/003602-2022

## Notice URLs

- http://health.atamis.co.uk
- https://health-family.force.com/s/Welcome
- https://healthfamily.force.com/s/Welcome
- https://supplierregistration.cabinetoffice.gov.uk
- https://www.england.nhs.uk/
- https://www.england.nhs.uk//
- https://www.gov.uk/courts-tribunals

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-0314ad. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-0314ad.json.